Table 2 Comparison of baseline characteristics between cure of the ulcerative lesions group and not
Variables | Cure of the ulcerative lesions (n = 28) | Not (n = 43) | *P value |
|---|---|---|---|
Male, n (%) | 10 (35.7%) | 12 (27.9%) | 0.6011 |
Age (years) | 40.2 ± 12.3 | 38.3 ± 14.6 | 0.2659 |
Disease duration (entero-BD, months) | 49.6 ± 64.1 | 41.9 ± 45.6 | 0.8923 |
Multiple ulceration, n (%) | 7/28 (25.0%) | 17/43 (39.5%) | 0.3048 |
History of relapse, n (%) | 16/28 (57.1%) | 24/43 (55.8%) | 1.0000 |
History of perforation, n (%) | 7/28 (25%) | 3/43 (6.98%) | 0.0425* |
History of surgery, n (%) | 5/28 (17.9%) | 3/43 (6.98%) | 0.2495 |
Concomitant CS use, n (%) | 15/28 (53.6%) | 27/43 (62.8%) | 0.4686 |
Concomitant CS dose (mg/day) | 14.5 ± 20.5 | 15.8 ± 19.2 | 0.5661 |
Concomitant colchicine use, n (%) | 7/28 (25%) | 23/43 (53.5%) | 0.0265* |
Concomitant drug use, n (%) (MTX, MS/SSZ, AZ) | 26/28 (92.9%) | 34/43 (79.1%) | 0.1812 |
Concomitant MTX use, n (%) | 21/28 (75%) | 20/43 (46.5%) | 0.0265* |
TNF-i use, n (%) | 25/28 (89.3%) | 24/43 (55.8%) | 0.0036* |
DAIBD | 67.3 ± 31.0 | 73.5 ± 36.7 | 0.6332 |